Corporation Financière M.R. pédale pour la cause et ramasse 15 825 $ lors du Grand défi Pierre Lavoie
July 24, 2019 08:00 ET
|
Corporation Financiere MR
La participation de Corporation Financière M.R. au marathon cycliste de 1000 km du Grand défi Pierre Lavoie a permis de ramasser 15 825 $ lors de l’édition 2019 et fut couronnée de succès. ...
Corporation Financière M.R. pedals for the cause and raises $15,825 during the Grand défi Pierre Lavoie
July 24, 2019 08:00 ET
|
Corporation Financiere MR
Corporation Financière M.R. 's participates in the Grand défi Pierre Lavoie’s 1000 km cycling marathon and raises $15,825 during the 2019 edition and was a great success. Corporation Financière M.R....
Corporation Financière M.R. annonce la promotion de Monsieur Simon Essiambre à titre d’associé
April 26, 2019 08:00 ET
|
Corporation Financiere MR
MONTRÉAL and LAVAL, Québec, 26 avr. 2019 (GLOBE NEWSWIRE) -- Corporation Financière M.R. est fière d’annoncer aujourd’hui la nomination de M. Simon Essiambre à titre d’associé du cabinet. ...
Corporation Financière M.R. announces the promotion of Mr. Simon Essiambre
April 26, 2019 08:00 ET
|
Corporation Financiere MR
MONTREAL and LAVAL, Québec, April 26, 2019 (GLOBE NEWSWIRE) -- Today, Corporation Financière M.R. is proud to announce the appointment of Mr. Simon Essiambre as the firm’s new partner. ...
Oral Mucositis Therapeutics Pipeline to Receive More Drug Designations from the USFDA in the Coming Years: P&S Market Research
April 06, 2018 01:30 ET
|
P&S Market Research
NEW YORK, April 06, 2018 (GLOBE NEWSWIRE) -- According to a new research report titled “Oral Mucositis Therapeutics Pipeline Analysis, 2017” published by P&S Market Research, Oral Mucositis...
Innovation Pharmaceuticals Brilacidin Meets Key Secondary Endpoint in Phase 2 Trial, Delays Onset of Severe Oral Mucositis (SOM); Latest Results Further Support Topline Data Showing Trial Met Primary Endpoint of Reducing Incidence of SOM
January 03, 2018 07:00 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today presented additional secondary endpoint...
Innovation Pharmaceuticals Obtains Direct Evidence of Molecular Pathways Modulation in Tumors from First Patients in Kevetrin Ph2a Ovarian Cancer Trial
December 27, 2017 07:30 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce highly encouraging...
Innovation Pharmaceuticals Completes Final Patient Visit in Phase 2b Study of Oral Prurisol for Psoriasis
December 21, 2017 07:30 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces all patient follow-up...
Innovation Pharmaceuticals Brilacidin Oral Mucositis Program Moving Forward Based Upon Positive Anchoring Phase 2 Results and Increased Brilacidin Franchise Value
December 18, 2017 07:30 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today is pleased to provide an update on the...
Innovation Pharmaceuticals Granted European Patent for Brilacidin in the Prevention of Oral Mucositis
December 12, 2017 08:00 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that the European Patent...